Trial 10M-14-1


A 2 part Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy in patients with unresectable or metastatic BRAF V600 mutant melanoma

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Michael Wong, M.D.
Other Trial Staff:  Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M., Torsten Fischer, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.